Krka d. d (KRK) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.056x

Based on the latest financial reports, Krka d. d (KRK) has a cash flow conversion efficiency ratio of 0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł128.16 Million ≈ $35.27 Million USD) by net assets (zł2.31 Billion ≈ $634.38 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Krka d. d - Cash Flow Conversion Efficiency Trend (2010–2024)

This chart illustrates how Krka d. d's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Krka d. d total liabilities for a breakdown of total debt and financial obligations.

Krka d. d Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Krka d. d ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Zhejiang Jingsheng Mech Electric
SHE:300316
-0.003x
Campbell’s Co
NYSE:CPB
0.069x
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
0.123x
Sartorius Aktiengesellschaft
XETRA:SRT3
0.020x
Oracle Financial Services Software Limited
NSE:OFSS
0.140x
Baiyin Nonferrous Group Co Ltd
SHG:601212
0.043x
Zions Bancorporation
NASDAQ:ZION
0.064x
AZUL SA PFD ADR 1
F:8AZA
N/A

Annual Cash Flow Conversion Efficiency for Krka d. d (2010–2024)

The table below shows the annual cash flow conversion efficiency of Krka d. d from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see KRK company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 zł2.24 Billion
≈ $615.87 Million
zł360.93 Million
≈ $99.33 Million
0.161x +54.85%
2023-12-31 zł2.18 Billion
≈ $600.45 Million
zł227.25 Million
≈ $62.54 Million
0.104x -52.37%
2022-12-31 zł2.14 Billion
≈ $588.55 Million
zł467.65 Million
≈ $128.70 Million
0.219x +8.69%
2021-12-31 zł1.92 Billion
≈ $528.16 Million
zł386.10 Million
≈ $106.26 Million
0.201x -2.30%
2020-12-31 zł1.75 Billion
≈ $482.12 Million
zł360.76 Million
≈ $99.29 Million
0.206x -1.75%
2019-12-31 zł1.67 Billion
≈ $458.92 Million
zł349.52 Million
≈ $96.19 Million
0.210x +11.35%
2018-12-31 zł1.54 Billion
≈ $423.90 Million
zł289.95 Million
≈ $79.80 Million
0.188x +22.92%
2017-12-31 zł1.49 Billion
≈ $409.44 Million
zł227.83 Million
≈ $62.70 Million
0.153x +3.61%
2016-12-31 zł1.44 Billion
≈ $397.53 Million
zł213.49 Million
≈ $58.76 Million
0.148x -25.23%
2015-12-31 zł1.41 Billion
≈ $386.95 Million
zł277.94 Million
≈ $76.49 Million
0.198x +56.41%
2014-12-31 zł1.35 Billion
≈ $372.06 Million
zł170.87 Million
≈ $47.03 Million
0.126x -44.37%
2013-12-31 zł1.33 Billion
≈ $366.75 Million
zł302.75 Million
≈ $83.32 Million
0.227x +1.26%
2012-12-31 zł1.24 Billion
≈ $341.41 Million
zł278.33 Million
≈ $76.60 Million
0.224x +3.51%
2011-12-31 zł1.14 Billion
≈ $313.68 Million
zł247.06 Million
≈ $67.99 Million
0.217x +25.79%
2010-12-31 zł1.05 Billion
≈ $289.89 Million
zł181.52 Million
≈ $49.96 Million
0.172x --

About Krka d. d

WAR:KRK Poland Drug Manufacturers - Specialty & Generic
Market Cap
$8.81 Billion
zł32.01 Billion PLN
Market Cap Rank
#2478 Global
#10 in Poland
Share Price
zł1048.00
Change (1 day)
-0.19%
52-Week Range
zł758.00 - zł1060.00
All Time High
zł1060.00
About

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company's prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolis… Read more